Newsroom of

Polaryx Therapeutics, Inc

140 E. Ridgewood Avenue, Suite 415, South Tower,
Paramus, NJ 07652

Polaryx Therapeutics, Inc. is solely dedicated to developing drug candidates for late infantile neuronalceroid lipofuscinosis (LINCL) and other forms of NCL, for which there is currently no patient-friendlytreatment option available.

Polaryx Therapeutics Receives Orphan Drug Designation From the U.S. FDA for PLX-200 for Rare Pediatric Disease

Polaryx Therapeutics, Inc, a biotech company developing oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and for other forms of NCL, commonly known as Batten disease, has been granted Orphan Drug Designation from the U.S. FDA for…


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login